Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients
NCT05027269
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DM1
Los Angeles, California, United States
View Trial DetailsNCT Number: NCT05006924
Myotonic Dystrophy type 1 (DM1) is a multisystem disease that causes muscle weakness and myotonia. As a result upper limb function might become impaired. In this study we will examine patients with DM1 and record their upper limb function. We will will use a battery of patient reported outcomes (PROs) and Outcome measures (OMs) in order to evalute which ones are suitable for use in clinical practise and research studies.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Haukeland University Hospital, Bergen, Norway
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 30-45 minutes
Functional test
Time frame: 1-3 minutes
Fine motor function test
Time frame: 1-3 minutes
Measures hand strenght
Time frame: 1-3 minutes
Measures finger strenght
Time frame: 5 min
A measure of manual ability for adults with upper limb impairments. The scale measures a person's ability to manage daily activities that require the use of the upper limbs, whatever the strategies involved. Consists of 22 questions (18 to be answered by adults). The categories are easy, difficult or unable to perform. The querionnaire gives a sum score where higher score equals better function.Score from 0 to 36
Time frame: 5 min
A measure of activity limitations for patients with upper and/or lower limb impairments. The scale measures a patient's ability to perform daily activities requiring the use of the upper and/or the lower limbs, whatever the strategies involved. Consists of 22 questions (18 to be answered by adults). The categories are easy, difficult or unable to perform. The questionnaire gives a sum score where higher score equals better function. Score fror 0 to 36
Time frame: 8-15 minutes
Motor impairment of trunk measured by functional testing. Six subdomains measuring stability and mobility of trunkal movement. Min score 0 - Max score 16. Higher score indicates better function.
Time frame: 1-3 minutes
Dynamic balance test
Time frame: 5-10 minutes
This a compostie measurement that is a Questionnaire. Patient reported outcome measure. Generic health related quality of life assesses each of the 7 PROMIS domains (depresseion, anxiety, physical function, pain, fatigue, sleep disturbance and ability to participate in social roles). The PROMIS 29 questionnaire contains 4 questions from each of seven PROMIS contents (physical function, depression, anxiety, fatigue, sleep disorder, participation in social activities and pain interaction) and 1 question from the intensity of pain. Each item has 5 answer options (from 1 to 5), only pain intensity has 11 answer options (from 0 to 10). From the sum of the answers to each question in the domain, the total raw score for each domain is calculated, resulting in seven domain scores, each between 4 and 20.
Time frame: 5 minutes
Questionnaire to be filled in under guidance of interviewer. Patient reported outcome measure of apathy. 14 questions, each of which is scored on a 4-point scale of 0-3, and apathy is rated as severer as the total score (0-42) increases
Time frame: 10 minutes
Cognitive assessment screening questionnaire. To be filled out in an interview setting. Score from 0 to 30, where a higher score indicates a better cognitive function. A score of 26 or more is considered normal.
Time frame: 10 minutes
Spirometry with FVC (Forced Vital Capasity)
Time frame: 10 minutes
PEF (Peak Expiratory Flow).
Oslo University Hospital
Other
Acronym: SOUL-DM1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05027269
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DM1
Los Angeles, California, United States
View Trial DetailsNCT06204809
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn
Irvine, California, United States
View Trial DetailsNCT05479981
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DM1
Los Angeles, California, United States
View Trial DetailsNCT03424460
Cardiovascular Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Paris, Île-de-France Region, France
View Trial Details